Press Releases

Press Releases

Date Title  
Jun 04, 2024 Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE --(BUSINESS WIRE)--Jun. 4, 2024-- Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 6, 2024 , starting at 10:00 a.m. Pacific Time .
Jun 03, 2024 Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028
$118.1 million , or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment Repurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million cash on
May 15, 2024 Omeros Corporation Reports First Quarter 2024 Financial Results
– Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--May 15, 2024-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications
May 10, 2024 Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
SEATTLE --(BUSINESS WIRE)--May 10, 2024-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024 , on Wednesday, May 15, 2024 , after the market closes. Omeros management will host a conference call and
May 09, 2024 Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation -- SEATTLE --(BUSINESS WIRE)--May 9, 2024-- Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in
Apr 01, 2024 Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
– Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Apr. 1, 2024-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications
Mar 27, 2024 Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
SEATTLE --(BUSINESS WIRE)--Mar. 27, 2024-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023 , on Monday, April 1, 2024 , after the market closes. Omeros management will host a conference call and
Feb 20, 2024 Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
SEATTLE --(BUSINESS WIRE)--Feb. 20, 2024-- Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Feb 01, 2024 Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
– Expands DRI royalty deal on U.S. net sales of OMIDRIA – – Expanded deal brings Omeros $115 million upfront payment and opportunity for additional $55 million in sales-based milestones – SEATTLE --(BUSINESS WIRE)--Feb. 1, 2024-- Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI